Indee Labs

Indee Labs is a private, platform technology company focused on transforming the development and manufacturing of engineered cell therapies, such as T-cell immunotherapies. Its patented Hydropore™ system uses a novel microfluidic method to deliver genetic payloads into immune cells quickly and with high viability, positioning it as a potential solution to key industry challenges like cost, scalability, and safety associated with viral vectors. The company is currently in a pre-revenue, research-use-only (RUO) stage, with strategic partnerships and investments aimed at developing its technology towards clinical and commercial applications. Its roadmap includes progressing from an RUO system to a clinical-grade manufacturing tool.

Hydropore™, a non-viral delivery platform using microfluidic vortex shedding (µVS) to transiently permeabilize cells for the rapid introduction of small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells.

Indee Labs competes in the non-viral cell engineering market against dominant players like Lonza (Nucleofector), MaxCyte (Flow Electroporation), and Thermo Fisher Scientific. It also competes with numerous startups developing alternative physical delivery methods (e.g., sonoporation, nano-electroporation) and companies working on improved viral or hybrid vector systems. Its differentiation hinges on the claimed gentleness and speed of its microfluidic vortex shedding approach.